In what has been a transformative year for ulcerative colitis (UC) treatment, the IL-23 class has solidified its role as a key therapeutic treatment option. With Johnson & Johnson’s Tremfya now ...
By speaking to the parties related to the recent headlines emerging out of the Geneva Camp, we find a simmering drug war, its victims, causes and a camp life in the dark ...
Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat near-sightedness in children after it failed to slow the condition's progression, sending its shares ...